Edgewise Therapeutics, Inc.

EWTX

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001710072

SEC filings (opens in a new tab)

In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 9, 2026: $5.34B
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $1.90M in total: 5
13F holdersQ2 2026, +15 vs. previous quarter: 226
13F valueReported value at the end of Q2 2026: $4.82B
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: –; No comparable prior period
Net income, FY2025: -$167.8M; No comparable prior period
Free cash flow, FY2025: -$144.1M; No comparable prior period
Revenue, Q3 FY2026: –; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 15, 2026.

Short interest: 11.8M; Shares sold short
Change: +527.4K; +4.7% vs. previous
Days to cover: 8.48; At average daily volume

Superinvestors holding EWTX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding EWTX at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Edgewise Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Aug 14, 2026 (view filing)4:54 PM ET	Aug 12-13	2 days	Donovan Joanne M.CMO	SSale	−9.44K	$43.71	−$412.7K	−52.3%8.63K after	From original5 lots
Aug 14, 2026 (view filing)4:53 PM ET	Aug 12	2 days	Russell Alan JChief Scientific Officer	SSale	−5.90K	$43.73	−$258.0K	−15.8%31.5K after	From original3 lots
Aug 14, 2026 (view filing)4:53 PM ET	Aug 12	2 days	Moore John RGeneral Counsel	SSale	−5.02K	$43.82	−$219.8K	−22.1%17.7K after	From original4 lots
Aug 14, 2026 (view filing)4:53 PM ET	Aug 12	2 days	Derakhshan BehradChief Business Officer	SSale	−5.10K	$43.81	−$223.4K	−13.8%31.8K after	From original4 lots
Aug 14, 2026 (view filing)4:52 PM ET	Aug 12	2 days	Koch KevinPresident and CEO	SSale	−18.0K	$43.68	−$785.0K	−25.5%52.5K after	3 lots
Jul 2, 2026 (view filing)5:21 PM ET	Jul 1	1 day	Russell Alan JChief Scientific Officer	SSale	−200.0K	$39.41	−$7.88M	−89.1%24.6K after	2 lots10b5-1
May 5, 2026 (view filing)	May 4-5	1 day	Donovan Joanne M.CMO	SSale	−55.2K	$37.88	−$2.09M	−92.7%4.37K after	2 lots
Apr 2, 2026 (view filing)	Apr 1	1 day	Donovan Joanne M.CMO	SSale	−28.7K	$32.31	−$926.1K	−74.9%9.60K after	10b5-1
Mar 31, 2026 (view filing)	Mar 31	Same day	Donovan Joanne M.CMO	SSale	−21.3K	$32.12	−$685.4K	−69.0%9.60K after	10b5-1
Mar 30, 2026 (view filing)	Mar 27	3 days	Donovan Joanne M.CMO	SSale	−16.4K	$30.98	−$506.8K	−63.0%9.60K after	2 lots10b5-1

Top 10 13F holders, Q2 2026

See all 226 holders

The largest institutional positions in Edgewise Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding EWTX in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
OrbiMed Advisors LLC	15,518,492	$630.5M	11.94%	00.0%	Unchanged
Paradigm Biocapital Advisors LP	10,215,455	$415.1M	7.77%	+2,850,417+38.7%	Added
Ra Capital Management, L.P.	8,392,730	$341.0M	2.96%	−2,035,707−19.5%	Reduced
BlackRock, Inc.	6,606,336	$268.4M	0.00%	+133,345+2.1%	Added
Jupiter Topco LLC	6,075,331	$246.9M	0.10%	+6,075,331	New
FMR LLC	5,489,135	$223.0M	0.01%	+4,472,083+439.7%	Added
Novo Holdings A/S	5,350,000	$217.4M	12.67%	00.0%	Unchanged
Driehaus Capital Management LLC	4,728,623	$192.1M	1.11%	+250,681+5.6%	Added
Perceptive Advisors LLC	4,373,974	$177.7M	2.76%	−50,000−1.1%	Reduced
Vanguard Capital Management LLC	3,860,670	$156.9M	0.00%	+72,509+1.9%	Added

Holders of 5% or more of EWTX

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Edgewise Therapeutics, Inc..

Largest holders of EWTX from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
OrbiMed Advisors LLC	13D/A	14.50%15.3M shares	–	Apr 8, 20215 filings	May 12, 2025	SEC
Paradigm Biocapital Advisors LP	13G/A	9.50%10.2M shares	+3.30 ppfrom 6.20%	Feb 3, 20253 filings	Aug 14, 2026	SEC
Ra Capital Management, L.P.	13G/A	7.80%8.39M shares	−2.10 ppfrom 9.90%	Feb 14, 20225 filings	Aug 14, 2026	SEC
Janus Henderson Group PLC	13G	5.50%5.92M shares	+0.80 ppfrom 4.70%	Feb 14, 20255 filings	May 15, 2026	SEC
BlackRock, Inc.	13G/A	5.50%5.82M shares	–	Oct 22, 20243 filings	Jul 17, 2025	SEC